1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
(
- Contribution to journal › Article
- 1999
-
Mark
Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells
(
- Contribution to journal › Article